Podcasts about CRS

See omnystudio.com/listener for privacy information.

tracklist and more info: https://www.bestdrumandbass.com/podcast604/YO my friends, we are back at it with another week of heavy hitters! This week we have Brijawi in the guest mix coming to rock with us, and you know in the resident seat as usual is Bad Syntax bringing the freshest unreleased madness. Lock it in, its time to blast off.Subfuze - Avalanche / Brash Out now on Abducted LTDDownload / Stream: bestdrumandbass.com/altd143/Supported by: Gydra, Manta, Doc Scott, Stonx, MV, Akrom, Pish Posh, DJ Odi, ESKR, Bad Ace, Nox, MYGR, The In Kill, Sindicate, Bytecode, Korax, Protoss, Jane Doe DNB, Guddah, Quannum Logic, ARI-ON, Titanz, Metric, Hijk, Nightstalker, Insom, Unknown Konflikt, SeanTron, Autopsy, Octane Amy, Critical Control Point, Lee UHF, Subconscious BSC, The d34d b34t, Ollie Duracell, Crackindomes, Confusion, CRS , Affirmation, J. Augustus, Lennart Hoffmann, Warlock, BassDrive.com, Inside DnB, Sinuous Recordings and more!Subscribe to the podcast: bestdnb.com/podcast

The House passes a CR with two months left on the clock.A punt is a concession you make when you've run out of downs. The House made this one on first down. With more than two months left in the fiscal year and none of the twelve appropriations bills finished, it passed a continuing resolution funding the government at fiscal year 2026 levels through December 4th, largely on party lines. Appropriations Chair Tom Cole calls the bill clean. Steve Ellis and TCS Director of Research and Policy Josh Sewell take that word apart. Clean means no partisan poison pills. It does not mean neutral. Extending the current base level for the Pentagon, for the Justice Department, for every agency, is a choice about priorities — just one nobody has to vote on.Then there's the White House anomalies list, transmitted before every CR. Some items are housekeeping: updating a program date, dropping funding for an inauguration three years away. Others are not. The list includes $1 billion to start building a Trump-class battleship whose design isn't finished — the same concurrent-design approach that produced an F-35 fleet fully mission capable about 30 percent of the time. It includes $3.2 billion in defense-wide procurement justified only by information available at a higher classification. And it would shield unobligated One Big Beautiful Bill Act funds from the standard 8 percent sequestration clawback, while the Pentagon sits on $89 billion of that money unspent and asks separately for $73 billion for the war with Iran.Steve and Josh also dig into Senate Majority Leader Thune's threat to fall back on reconciliation if Democrats won't deal, the Lankford-Hassan bill that would make automatic two-week CRs painful enough to keep members in town and working, and the record underneath all of it: Congress has finished all twelve appropriations bills on time four times in more than fifty years. The last was 1997.

How can bispecific antibodies be safely delivered outside the hospital? Rahul Banerjee, MD and Ajay Nooka, MD discuss outpatient step-up dosing, prophylactic tocilizumab, CRS management, and practical tips for implementing bispecific therapy in academic and community practice.  

In this podcast episode, Natalie S. Callander, MD, and Tom Martin, MD, discuss the optimal approaches for the determination of whether a patient with high-risk SMM requires treatment or observation, including: Contemporary Risk Stratification Interpreting Evidence for Early Intervention Treatment vs Observation: Patient Selection Treatment Selection and Sequencing Considerations Safety, Monitoring, and Supportive Care Implementation in Practice Shared Decision-making and Patient Communication Emerging Therapies and Clinical Trials Presenters:  Natalie S. Callander, MD Professor of Medicine Director, Myeloma Clinical and  Cellular Therapy Program University of Wisconsin Carbone  Cancer Center Madison, Wisconsin Tom Martin, MD Professor of Medicine Associate Chief, Hematology/Oncology UCSF Medical Center San Francisco, California Link to full program:https://bit.ly/4wqpYzU Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On commence par le premier… Quelle est loin l'humiliation subie par le président ukrainien dans le bureau ovale en février de l'année dernière… Mardi 28 juillet, à Washington, relève Le Monde à Paris, « Volodymyr Zelensky a soigné sa nouvelle relation avec Donald Trump et a décroché une victoire au Sénat américain », avec le vote pour l'extension des sanctions contre la Russie. En effet, pointe le journal, « le ton a radicalement changé. Donald Trump lui-même s'en étonne. "On a vraiment une bonne relation. Difficile à croire, non ?", commentait-il, début juillet, depuis le sommet de l'Otan, à Ankara, où les deux hommes ont été vus riant ensemble ». Et Le Monde de s'interroger : « Est-ce le penchant naturel de l'Américain à mépriser les "losers" (les perdants) et à admirer les "winners" (les gagnants) qui l'a obligé à regarder Kiev différemment ? Est-ce l'admiration pour les prouesses technologiques de l'armée ukrainienne, devenue une référence dans la fabrication de drones tueurs ? Ou est-ce l'agacement de constater que Vladimir Poutine n'a aucune volonté réelle de négocier la paix qu'espère tant le président des États-Unis ? ». En tout cas, poursuit le journal, « ces derniers mois, alors que l'Ukraine reprenait l'ascendant psychologique, résistant sur le champ de bataille, torpillant les infrastructures pétrolières russes et encerclant la Crimée, Donald Trump a cessé de voir en Volodymyr Zelensky un "dictateur" ayant réussi à embobiner son prédécesseur, Joe Biden, pour obtenir du matériel militaire. Le milliardaire loue désormais "le boulot incroyable" que le président ukrainien accomplit et promet de l'aider ». En position de force Le Washington Post renchérit : « Cette fois-ci, Zelensky est arrivé à Washington en position de force. Le Sénat s'est mobilisé pour faire adopter de nouvelles sanctions contre la Russie. Laura Loomer, blogueuse pro-Trump influente qui, la semaine dernière, avait renié des années de critiques lors d'un long séjour à Kiev, a publiquement apporté son soutien à l'Ukraine. (…) "Je me sens vraiment mal d'avoir minimisé les souffrances des Ukrainiens ces cinq dernières années", a-t-elle affirmé avant de poursuivre : "nous avons été tellement manipulés par la propagande russe sans même nous en rendre compte" ». Enfin, croit savoir le Washington Post, « les envoyés spéciaux de Trump, Steve Witkoff et Jared Kushner, pourraient bientôt effectuer leur premier voyage à Kiev ». La consécration pour Zinédine Zidane Un certain Zinedine Zidane également à la Une… « Une passion française », s'extasie L'Equipe en première page avec cette photo du nouveau sélectionneur de l'équipe de France de football, tout sourire. Lui qui habituellement a l'air « renfrogné », estime pour sa part le Wall Street Journal. Non, hier, pour Zidane, c'était la consécration : « Zinédine Zidane à la tête des Bleus, une évidence enfin concrétisée », relève Le Temps à Genève : « Ils étaient faits l'un pour l'autre mais ont mis vingt ans à se retrouver. Hier, l'ancien numéro 10 de l'équipe de France a officiellement été nommé au poste de sélectionneur, après avoir patienté longtemps, dans l'ombre de Didier Deschamps ». En effet, pointe Libération, « après quatorze ans d'attente, l'ancien meneur de jeu succède à Didier Deschamps avec l'ambition de prolonger les succès des Bleus, dans un contexte où la FFF mise autant sur son aura que sur ses qualités d'entraîneur ». « Car il l'a avoué, souligne Le Parisien : pendant cinq ans, depuis son départ du Real Madrid en 2021, l'ancienne gloire des Bleus n'attendait que ce moment. Les propositions n'ont pas manqué, il les a toutes balayées. Son envie était dirigée vers une seule destination : l'équipe de France, qui l'a vu passer des minimes aux A avant qu'il ne devienne l'idole de tout un peuple un soir de 12 juillet 1998 contre le Brésil ». Hier midi, après sa conférence de presse, relate Le Figaro, « sous le soleil parisien, Zizou sort boulevard de Grenelle et s'offre un bain de foule face aux supporteurs des Irrésistibles et aux nombreux badauds présents pour l'occasion. Même les CRS profitent de l'instant et prennent des photos. Du jamais vu dans l'histoire de la FFF. Après un déjeuner avec le président pour régler des dossiers, la star du jour quitte les lieux. Des étoiles plein les yeux. La magie a opéré. Prochain rendez-vous à la rentrée. L'ère Zinédine Zidane est lancée ».

In this episode of Real Estate Real Talk, Leigh Brown, CRS, draws on her decades of real estate experience to discuss why education, community involvement, and staying informed are essential to long-term success. She takes a closer look at the growing influence of data centers on local markets and property values, and explains why REALTORS® should be actively engaged in planning and zoning conversations. Tune in to gain practical insights that will help you better advocate for your clients, strengthen your community, and stay ahead of emerging industry trends.

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry examine three Express Entry bonus-point factors that could soon be removed or refined—up to 50 points for French-language ability, 30 points for Canadian education, and 15 points for having a sibling in Canada. They explain why IRCC considers these factors weaker predictors of long-term economic success, which applicants are most exposed to the proposed changes, and how candidates should prepare before new ministerial instructions alter the Comprehensive Ranking System (CRS). Key Topics Discussed The proposed removal or refinement of French, Canadian education, and sibling bonus points Why IRCC considers these factors weaker predictors of long-term economic success Why French may remain valuable through category-based Express Entry draws Practical strategies for applicants currently relying on these additional CRS points Key Takeaways Applicants could lose up to 95 CRS points across French-language ability, Canadian education, and having a sibling in Canada if the proposed reforms are implemented. Removing the 50 French-language bonus points would not necessarily eliminate French category-based draws, which may continue offering candidates a pathway with lower CRS cut-offs. Applicants with one or two-year Canadian college credentials and those relying on sibling points may be the most exposed, while IRCC may preserve education points for certain graduate-level programs. Candidates should calculate their CRS scores without these additional points and consider strengthening their education, language ability, Canadian work experience, or earnings. Quotes from the Episode: Mark Holthe: "You cannot look at your current situation, the current rules, and then make your long-term decisions based on the way the world looks now." Alicia Backman-Beharry: "Understand if all these points for French and for siblings and for your Canadian education go away, are you still in a relatively strong position?" Links and Resources How to list your Canadian spouse in an Express Entry Application Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

At the 2026 National ICE-T Conference in Orlando, CancerNetwork® sat down with a variety of expert researchers and clinicians to discuss the latest developments in immune effector therapy across different hematologic oncology populations. Sessions at the meeting covered practical considerations for integrating CAR T-cell therapies, bispecific antibodies, and other modalities into the treatment of those with multiple myeloma, lymphoma, and other hematologic malignancies.First, Benjamin Diamond, MD, an assistant professor of Clinical Medicine, a member of the Sylvester Myeloma Institute, and a member of the Myeloma Genomic Lab at the University of Miami Miller School of Medicine, spoke about his presentation reviewing bispecific antibodies for the management of multiple myeloma. In his session, Diamond stated that bispecific T-cell engagers are altering the landscape of multiple myeloma care and will eventually become an option in the frontline setting. With many products to choose from, Diamond emphasized sequencing these novel therapies wisely and stressed aggressive infection prophylaxis as a mandatory facet of care.Next, Tiba Al Sagheer, PharmD, BCOP, BCACP, a pharmacy quality improvement coordinator for transplant and cellular therapy at Miami Cancer Institute of Baptist Health South Florida discussed her presentation focused on defining new thresholds for monitoring and mitigating toxicities associated with CAR T-cell therapy. She described considerations for balancing early toxicity intervention against the risk of blunting efficacy depending on the specific CAR T-cell product used during treatment. Ultimately, she noted that that there is still no definitive answer or threshold for initiating prophylaxis for toxicity associated with CAR T, and that differentiating between immune effector cell (IEC)–associated hemophagocytic lymphohistiocytosis (HLH)–like syndrome (IEC-HS) and cytokine release syndrome (CRS) represents an ongoing challenge in the field.Finally, Nikesh N. Shah, MD, and Carlos Silva Rondon, MD, shared their perspectives on a debate regarding the roles of bispecific antibodies and CAR T-cell therapies in relapsed/refractory follicular lymphoma. In his presentation, Shah, a hematologist-oncologist at Tampa General Hospital who specializes in hematologic malignancies, including aggressive lymphomas and acute lymphoblastic leukemia, took the position that bispecific antibodies should be used prior to CAR T-cell therapy for most patients, although both treatments have utility in the field. Silva Rondon, a hematologist, oncologist, and bone marrow transplant specialist at Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System/Memorial Cancer Institute in Pembroke Pines, advocated for CAR T-cell therapy during the debate but acknowledged that both modalities can make up a complementary strategy for overcoming relapsed/refractory follicular lymphoma.References Diamond B. Bispecific antibodies for the management of multiple myeloma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Sagheer TA. Thresholds and therapeutics: a precision approach to CAR T toxicity management. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Shah N. Debate: bispecific antibodies vs CAR-T in follicular lymphoma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Silva C. CAR-T cell therapy for relapsed follicular lymphoma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL.

Tracklist and more info: https://www.bestdrumandbass.com/podcast603/ ‎RELEASE DAY IS HERE MY FRIENDS! One of my favorite up and coming artists has a brand new single and he is here in the guest mix to help promo it today. Subfuze got the sound to keep you rocking, so lock it in and go check out that new single! Subfuze - Avalanche / Brash Out now on Abducted LTDDownload / Stream: bestdrumandbass.com/altd143/Supported by: Gydra, Manta, Doc Scott, Stonx, MV, Akrom, Pish Posh, DJ Odi, ESKR, Bad Ace, Nox, MYGR, The In Kill, Sindicate, Bytecode, Korax, Protoss, Jane Doe DNB, Guddah, Quannum Logic, ARI-ON, Titanz, Metric, Hijk, Nightstalker, Insom, Unknown Konflikt, SeanTron, Autopsy, Octane Amy, Critical Control Point, Lee UHF, Subconscious BSC, The d34d b34t, Ollie Duracell, Crackindomes, Confusion, CRS , Affirmation, J. Augustus, Lennart Hoffmann, Warlock, BassDrive.com, Inside DnB, Sinuous Recordings and more!Subscribe to the podcast: bestdnb.com/podcast

In today's episode, we spoke with Joshua K. Sabari, MD. Dr Sabari is an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, and director of High Reliability Organization Initiatives at NYU Langone Health's Perlmutter Cancer Center New York. In our exclusive interview, Dr Sabari discussed the complexities of managing small cell lung cancer (SCLC) across both academic and community settings, emphasizing that nothing about this disease is straightforward. He stressed the importance of rapid diagnosis and staging, ideally within 48 to 72 hours given how quickly patients can deteriorate, and noted that in his own academic practice, approximately 30% of patients never reach second-line therapy, a figure that climbs to 50% to 60% in the community setting.He highlighted 2 areas where community implementation frequently breaks down: first-line maintenance and second-line therapy. Regarding maintenance, Dr Sabari underscored the need to counsel patients about the combination of atezolizumab (Tecentriq) plus lurbinectedin (Zepzelca) from the outset of treatment, so the transition after 4 cycles of chemoimmunotherapy is not a surprise. In the second-line setting, he addressed the practical challenges of administering tarlatamab-dlle (Imdelltra), a CD3 x DLL3 bispecific T-cell engager, noting that the first 2 doses require inpatient monitoring given the risks of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). However, he noted that these monitoring resources may not be readily available outside of academic centers.The discussion also covered the evolving role of the multidisciplinary care team, with Dr Sabari highlighting the outsized impact of dedicated thoracic pharmacists in educating patients, monitoring for adverse effects (AEs), and intervening early, particularly with novel agents whose AE profiles are still being characterized. He shared real-world examples of coordination saves, including a radiologist who flagged early pneumonitis and a patient receiving tarlatamab who developed subtle cognitive changes that were initially missed.Finally, Dr Sabari outlined the top educational gaps for community teams: understanding the biological heterogeneity of SCLC, recognizing when and how to use emerging agents such as tarlatamab and obrixtamig (BI 764532), and developing fluency in managing novel toxicities including CRS, ICANs, and interstitial lung disease associated with antibody-drug conjugates.

In this informative episode we dived into the world of CAR T-cell therapies for multiple myeloma. In this ToxCheck episode, we focused on the available CAR-T options, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and discussed their side effects, management strategies, and the importance of patient education.   We were joined by myeloma specialists Caitlin Costello, MD, from UC San Diego Health, and Joshua Richter, MD, from Mount Sinai, who shared their insights on the acute and chronic side effects associated with CAR-T therapies. Learn about the common toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), as well as the role of prophylactic treatments and the importance of bridging therapy.   This episode emphasized the critical collaboration between community oncologists and academic institutions to ensure patients receive the best care possible. Tune in to understand how to navigate the complexities of CAR-T therapies and empower your patients with the knowledge they need.   Key Topics: Overview of CAR-T therapies for multiple myeloma Common side effects: CRS and ICANS Management strategies for acute and chronic toxicities The role of prophylactic treatments Importance of communication between community and academic oncologists   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #CARTtherapy, #MultipleMyeloma, #CRS, #ICANS, #OncologyBrothers

In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including: The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone, levetiracetam, and/or high-dose methylprednisolone Infection susceptibilities associated with BCMA-targeted bispecific antibodies and how this varies for GPRC5D-directed targets throughout therapy How to set up and maintain a REMS program Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Syeda Saba Kareem, PharmD, BCOP Clinical Pharmacy Supervisor Malignant Hematology Moffitt Cancer Center Tampa, Florida Sara A. Scott, PharmD, BCOP Clinical Pharmacy Specialist,  Multiple Myeloma Emory Winship Cancer Institute Atlanta, Georgia Link to full program: https://bit.ly/3RUyrMx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

320 000, c'est le nombre d'étudiants laissés sur le carreau en 2025 par la plateforme parcoursup. Une sélection à l'entrée de l'université voulue par les macronistes et appliquée avec zèle par certaines universités. Y compris celles qui ont une longue histoire de gauche, comme l'université de Nanterre. Et gare aux syndicats étudiants qui voudraient mener des actions pour débloquer les situations de ceux qu'on appelle désormais les “sans facs”. Certains militants de l'UNEF, 8 pour être plus précis, en ont fait les frais. En effet, ces derniers ont été convoqués les 29 et 30 juin derniers au commissariat de Nanterre. Selon les militants, c'est un acharnement de la part de la direction de l'établissement, qui n'avait déjà pas hésité à faire intervenir les CRS pour défaire ces occupations. L'UNEF n'entend pas lâcher la lutte pour autant. Ce d'autant que d'autres problématiques se sont rajoutées à parcours sup depuis : à commencer par la hausse des frais d'inscription et plus récemment la fin des APL pour les étudiants étrangers. Ainsi les syndicats sont de plus en plus réprimés par les directions de leurs facs alors que la situation des étudiants en France est de plus en plus catastrophique. Pour en parler, Irving Magi reçoit Hajar, trésorière de l'UNEF Nanterre.

Tracklist and more info: https://www.bestdrumandbass.com/podcast602/ Welcome back my friends, ITS MY BIRTHDAY! (Today, July 17) We are celebrating by doing what we always do, bringing the fuckin basslines direct to you! This week we have Raw Session in the guest mix rocking out, and as always your resident mix by Bad Syntax. Lock it in, and rock it out, the birthday weekend has officially begun! N.A.P.S. 2026 presented by Abducted LTDFeaturing: Acidion / Bad Syntax / Basinys / Crvtch / Dark Adaptation / Diode / Dr.Uggist / Electron-C / Eskr / Evassive / FauxRealz / Goss & Subby / Messinian / Pish Posh / Skorpion / Sodie / Spiralus / Subfuze / Zaiaku / 9 WrenchesDownload / Stream: bestdrumandbass.com/altd142/Supported by: NOISIA, DJ Aphrodite, Doc Scott, Figure, Stonx, Nightstalker, Guddah, Akrom, Metric, dela Moon, 5AH5H, Abstr4ct, Bad Ace, The In Kill, Korax, MYGR, Acidion, Nox, Kozee, Protoss, Bytecode, Titanz, Contam, GroVe, ARI-ON, Subconscious BSC, Confusion, 360 Degrees, Crackindomes, Hijk, Stonerice, Drumad, Critical Control Point, Johannes Soppa, Lee UHF, The d34d b34t, Lennart Hoffmann, Octane Amy, Ollie Duracell, Dan, SeanTron, Insom, D_E_B_T, MV, Jay, J. Augustus, Affirmation, CRS and moreSubscribe to the podcast: bestdnb.com/podcast

This week on the Midweek Takeaway, Kevin Hornsby is joined by Jeremy Skillington and Cathal Friel from Poolbeg Pharma to discuss the company's latest clinical milestone after dosing the first patient in its Phase II trial for POLB 001.The discussion covers how the treatment is designed to prevent cytokine release syndrome (CRS) in patients receiving cancer immunotherapies, the significance of Poolbeg's partnership with Johnson & Johnson, the commercial opportunity in a multi-billion-dollar market, and why management has continued to back the company with significant personal investmentDisclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including: A Brief Overview of BCMA in Multiple Myeloma Advances in BCMA-Targeted Agents in Progressing Myeloma Selection of BCMA-Directed Therapies for Early Relapse MM Operational Challenges Faced by Oncology Pharmacists Regarding the Incorporation of BCMA-Targeted Agents in Practice Identifying and Managing Adverse Events Associated With BCMA-Directed Agents Presenters:  Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP Clinical Oncology Pharmacy Manager Atrium Health Levine Cancer Institute Charlotte, North Carolina Anthony Perissinotti, PharmD, BCOP Hematology Clinical Pharmacist Specialist University of Michigan Ann Arbor, Michigan Link to full program:https://bit.ly/4gCsgXt Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Watch on YouTubePoolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL clinical trial, marking the start of a key execution phase for its CRS prevention programme. With UCLH activated, further sites expected, interim data targeted for summer 2026 and partnering discussions ongoing, investors will be watching whether clinical progress can validate the programme's claimed commercial potential.

Poolbeg Pharma (AIM:POLB) CEO Jeremy Skillington joined Proactive's Stephen Gunnion to discuss the dosing of the first patient in its TOPICAL clinical trial evaluating POLB-001 for the prevention of cytokine release syndrome in multiple myeloma patients receiving Johnson & Johnson's teclistamab. Poolbeg expects to enrol up to 30 patients and remains on track to deliver interim clinical data by the end of summer 2026. Skillington highlighted growing interest from additional UK investigators, which could accelerate enrolment as more sites come online. Beyond the trial, Poolbeg is in active partnering discussions with both pharma companies developing CRS-associated cancer therapies and supportive care firms, supported by a comprehensive virtual data room. A positive FDA pre-IND meeting and research covering US payers across approximately 75 million lives strengthen the commercial case. "Having these clinical milestones and clinical data coming through throughout the summer — that really is what triggers the significant interest and potential transactions when it comes to partnering discussions," Skillington said. For more interviews with leading companies, visit the Proactive YouTube channel, give this video a like, subscribe to the channel and enable notifications so you never miss future content. #PoolbegPharma #POLB001 #JeremySkillington #MultipleMyeloma #Biotech #Pharma #ClinicalTrials #DrugDevelopment #CancerResearch #CytokineReleaseSyndrome #CRS #HealthcareInnovation #Investing #SmallCapStocks #ProactiveInvestors

WOW its a HUGE week its been for the NAPS crew! We hit #5 DNB release, and even broke the top 40 of all genres! I want to start off this episode with a heartfelt thank you to everyone who helped with that. This week we have one of the stars of the release, Acidion, in the guest mix to help rock out into the weekend! Lock it in, and if you havent yet PLEASE go check the latest release linked below! N.A.P.S. 2026 presented by Abducted LTDFeaturing: Acidion / Bad Syntax / Basinys / Crvtch / Dark Adaptation / Diode / Dr.Uggist / Electron-C / Eskr / Evassive / FauxRealz / Goss & Subby / Messinian / Pish Posh / Skorpion / Sodie / Spiralus / Subfuze / Zaiaku / 9 WrenchesDownload / Stream: bestdrumandbass.com/altd142/Supported by: NOISIA, DJ Aphrodite, Doc Scott, Figure, Stonx, Nightstalker, Guddah, Akrom, Metric, dela Moon, 5AH5H, Abstr4ct, Bad Ace, The In Kill, Korax, MYGR, Acidion, Nox, Kozee, Protoss, Bytecode, Titanz, Contam, GroVe, ARI-ON, Subconscious BSC, Confusion, 360 Degrees, Crackindomes, Hijk, Stonerice, Drumad, Critical Control Point, Johannes Soppa, Lee UHF, The d34d b34t, Lennart Hoffmann, Octane Amy, Ollie Duracell, Dan, SeanTron, Insom, D_E_B_T, MV, Jay, J. Augustus, Affirmation, CRS and moreSubscribe to the podcast: bestdnb.com/podcast

In this episode of the Oncology Brothers podcast, we tackled two real-world challenging cases in diffuse large B-cell lymphoma (DLBCL) alongside two lymphoma experts — Dr. Matthew Lunning from the University of Nebraska and Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. The central question: when faced with relapsed or transformed aggressive B-cell lymphoma, how do you choose between CAR-T cell therapy and bispecific antibodies, and how do you get patients through this safely?   Key topics discussed included: The role of CAR-T cell therapy in early relapsed DLBCL based on ZUMA-7 and TRANSFORM trial data, and practical strategies for bridging and holding therapy pre- and post-apheresis to safely deliver treatment. A comparison of axicabtagene ciloleucel versus lisocabtagene maraleucel in terms of efficacy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) rates, and outpatient feasibility. Management of transformed follicular lymphoma to double-hit DLBCL in the third-line setting, including the role of glofitamab, mosunetuzumab, polatuzumab, and epcoritamab as bridges to CAR-T cell therapy. The importance of early partnership between community oncologists and tertiary care centers to ensure patients access CAR-T and bispecific therapies in a timely manner. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Join us for this expert discussion on navigating the complex treatment landscape of relapsed and transformed aggressive B-cell lymphoma. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #DLBCL, #CARTTherapy, #BispecificAntibodies, #Hematology, #OncologyBrothers  

In this episode, Kurt Thompson, CRS, shares his extensive journey in real estate, emphasizing the importance of volunteer leadership, community involvement and continuous learning for professional growth. Discover how active participation in associations like RRC can transform your career and impact your community.  

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry examine one of the most controversial elements of Canada's proposed Express Entry reforms—the planned removal of the spousal points grid that currently reduces Comprehensive Ranking System (CRS) scores for applicants with accompanying spouses. They explain how the current system penalizes many married and common-law couples, why IRCC's own economic research suggests the policy does not accurately predict immigrant success, and what applicants should consider while waiting for the proposed changes to be implemented. Key Topics Discussed How the current spousal points grid reduces CRS scores for accompanying spouses Why IRCC's own research suggests spouse factors have little impact on long-term economic success The proposed removal of the spousal points grid and what it could mean for families Practical strategies for couples deciding whether to include a spouse on an Express Entry application Key Takeaways Under the current CRS system, applicants with accompanying spouses can lose up to 40 human capital points, depending on their spouse's education, language ability, and Canadian work experience. IRCC's own longitudinal research indicates that a spouse's education, language ability, and Canadian work experience have little measurable impact on the principal applicant's long-term economic outcomes. Removing the spousal grid would allow applicants to be assessed on their own human capital rather than their spouse's qualifications, helping reduce unintended penalties for families. Although the proposed reform has been announced, applicants must continue planning under the current rules until IRCC officially implements the changes. Quotes from the Episode: Mark Holthe: "It wasn't the spouse that reduced a family's success—the system simply assumed it did." Alicia Backman-Beharry: "The evidence doesn't support the spousal grid. It really functions as a penalty that doesn't reflect actual economic outcomes." Links and Resources How to list your Canadian spouse in an Express Entry Application Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

Its official, 600 episodes in the back pocket, and were only getting heavier! This week we have None Decay making their debut in the guest mix, and we also are celebrating the first annual N.A.P.S. release! If youre not familiar with the North American Producer Showcase, its about celebrating all the amazing talent we have here in North America. The release is the first in the series, and we will be giving 100% of all profits to the artists to help celebrate them. We hope youll join us in celebrating this amazing project!N.A.P.S. 2026 presented by Abducted LTDFeaturing: Acidion / Bad Syntax / Basinys / Crvtch / Dark Adaptation / Diode / Dr.Uggist / Electron-C / Eskr / Evassive / FauxRealz / Goss & Subby / Messinian / Pish Posh / Skorpion / Sodie / Spiralus / Subfuze / Zaiaku / 9 WrenchesDownload / Stream: bestdrumandbass.com/altd142/Supported by: NOISIA, DJ Aphrodite, Doc Scott, Figure, Stonx, Nightstalker, Guddah, Akrom, Metric, dela Moon, 5AH5H, Abstr4ct, Bad Ace, The In Kill, Korax, MYGR, Acidion, Nox, Kozee, Protoss, Bytecode, Titanz, Contam, GroVe, ARI-ON, Subconscious BSC, Confusion, 360 Degrees, Crackindomes, Hijk, Stonerice, Drumad, Critical Control Point, Johannes Soppa, Lee UHF, The d34d b34t, Lennart Hoffmann, Octane Amy, Ollie Duracell, Dan, SeanTron, Insom, D_E_B_T, MV, Jay, J. Augustus, Affirmation, CRS and more

Get ready for an inspiring and insightful episode of The Ash Said It Show as we sit down with a true powerhouse of the industry, Brianne Drake, who currently serves as the 2026 President of the Georgia Association of REALTORS®. As the first Black President in the 106-year history of the Georgia Association of REALTORS®, Brianne is a trailblazer whose distinguished 27-year career is defined by integrity, ethical leadership, and a deep commitment to service. Representing more than 47,000 members across the state of Georgia, Brianne shares her strategic vision for unity, professional leadership development, and the vital importance of advocacy in protecting homeownership rights. In this episode, we dive into Brianne's historic journey, exploring the milestones that allowed her to break barriers and rise as a respected leader on both the state and national levels, including her influential work as a Director for the National Association of REALTORS®. We also explore the power of political advocacy and why Brianne is so passionate about protecting private property rights, a commitment solidified by her 2025 induction into the National Association of REALTORS® RPAC Hall of Fame as a Major Investor. Beyond the politics and accolades, Brianne explains her client-first philosophy, sharing her deeply held belief that real estate is not simply about contracts or keys, but about people, families, and futures. We also celebrate her impressive professional legacy, including her 2026 recognition as one of the Georgia 100 Women of Excellence and the numerous formal resolutions honoring her contributions from the Georgia General Assembly. Whether you are a real estate agent seeking professional development, an aspiring industry leader, or a listener looking for a story of perseverance and dedication, this conversation with one of Georgia's most dynamic real estate experts is essential listening. Tune in now to learn how Brianne Drake is shaping the future of real estate. Web: https://garealtor.com/ Brianne Drake is a distinguished Georgia real estate industry leader serving as the 2026 President of the Georgia Association of REALTORS® (GAR). Representing more than 47,000 members throughout the state, she holds the historic distinction of being the first Black President in the 106-year history of the organization. As a Broker Associate and Global Real Estate Advisor with Atlanta Fine Homes Sotheby's International Realty, Brianne combines extensive market expertise with a commitment to client advocacy, integrity, and professional excellence. Brianne's professional career is defined by her deep involvement in local, state, and national REALTOR® governance and real estate policy. Her leadership portfolio includes serving as a Director for the National Association of REALTORS® (NAR) and as a dedicated member of the Membership Policy and Board Jurisdiction Committee. She previously served as the Chair of the Professional Standards Committee in 2023 and the Chair of the Professional Standards Interpretations and Procedures Advisory Board in 2024. As a champion of private property rights and industry advancement, Brianne was inducted into the NAR RPAC Hall of Fame as a Major Investor in 2025 and received the Georgia Association of REALTORS® Dick McCrudden Award in 2023 for her contributions to the REALTORS® Political Action Committee. Her professional accomplishments and impact on the Georgia real estate industry have been recognized by the Georgia General Assembly on multiple occasions. Brianne was honored on the floor of the Georgia Senate and House in 2026 through Senate Resolution 753 and House Resolution 1253, and previously in 2021, for her longstanding service to the community. In 2026, she also received the Georgia 100 Women of Excellence Resolution at the Georgia State Capitol in honor of Women's History Month. Her historical industry accolades include being named REALTOR® of the Year by the Metro South Association of REALTORS® in 2011 and 2018, as well as receiving the J.L. Christian Leadership Award in 2009 and 2011 and the President's Award in 2012. A native of Atlanta, Georgia, and an alumna of Georgia State University, Brianne utilizes a client-first philosophy that has established her as one of the state's most trusted real estate advisors. Her expertise is backed by a comprehensive suite of nationally recognized real estate designations, including ABR, AHWD, C2EX, CRS, GRI, SFR, and MRP. Through her work, she continues to provide exceptional experiences for families navigating the real estate market. "For me, real estate is not simply about contracts or keys; it's about people, families, and futures," says Brianne Drake, who remains dedicated to shaping the future of the real estate profession through advocacy and ethical leadership. - Ready to ignite the spark that levels up your entire life? Meet Ash Brown—the American powerhouse, motivational architect, and ultimate hype-woman dedicated to your personal and professional evolution. Ash is far more than a voice in the personal development space; she is a trusted ally who delivers a masterclass in real-talk wisdom and infectious energy. Whether you are navigating a crossroads or ready to scale your grandest ambitions, Ash fuels your journey with a high-octane blend of heart and hustle.

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry examine the return of job offers as a proposed factor in Express Entry and why this change could become one of the most significant elements of Canada's immigration reforms. They explain why job offer points were eliminated due to widespread LMIA fraud, how IRCC plans to reintroduce job offers through the proposed High-Wage Occupation framework, and why the new approach may benefit some applicants while leaving many essential workers behind. Key Topics Discussed Why job offer points were removed from Express Entry How LMIA fraud undermined the integrity of the system The proposed return of job offers tied to High-Wage Occupation classifications Why legitimate employers and many lower-wage essential workers may be affected by the new rules Key Takeaways Job offer points were eliminated because widespread LMIA fraud allowed individuals to purchase fraudulent job offers to gain additional CRS points. IRCC now proposes bringing job offers back through the High-Wage Occupation framework, focusing on occupations with higher national median wages. Applicants working in high-wage occupations may receive significant advantages, while many healthcare support workers, hospitality employees, and other essential occupations may receive little or no benefit. Although IRCC has outlined its direction, important details—including how qualifying job offers will be defined and how the new rules will be implemented—have not yet been finalized. Quotes from the Episode: Mark Holthe:"It wasn't the system that was broken—it was the enforcement that was broken." Alicia Backman-Beharry:"A real offer is the only offer of employment that should count under the old system or under the new system." Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Claiming Express Entry CRS points for a Job Offer in Canada Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry break down one of the most significant proposed changes to Express Entry: the new High-Wage Occupation (HWO) factor. They explain why IRCC believes pre-landing earnings are a strong predictor of economic success, how the proposed occupation-based multiplier could dramatically boost CRS scores for some applicants, and why many temporary residents—including international graduates and essential workers—could find themselves at a disadvantage. Key Topics Discussed Why IRCC is introducing the proposed High-Wage Occupation factor How occupation—not your personal salary—will determine eligibility The three proposed wage multiplier categories and how they may work Why some occupations could receive significant CRS boosts while others receive none Key Takeaways The proposed High-Wage Occupation factor is based on national median wages for occupations, not what an individual personally earns. Applicants working in higher-paying occupations may receive substantial additional CRS points under the new system. Many essential workers and international graduates in lower-wage occupations could become less competitive despite having Canadian education and work experience. Although the overall framework has been released, many implementation details—including the exact CRS points awarded—have not yet been finalized. Quotes from the Episode: Mark Holthe:"It is occupation-based, not individual-based." Alicia Backman-Beharry:"The system is not structurally reinforcing the wages of the people that we tend to devalue." Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

Tracklist and more info: https://www.bestdrumandbass.com/podcast599/Woah, almost to 600 episodes, and we are ramping up for the epic N.A.P.S. 2026 release next week in the resident mix with Bad Syntax. We also have BENNIT in the guest spot with a silky smooth guest mix that will help to get your weekend started proper. Lock it in, the weekend has begun!Direct Shift ft Sez'Nah - D.Y.C.A.G.Y.S / Bankruptcy [Abducted LTD]Download / Stream: bestdrumandbass.com/altd141/Supported by: MNDSCP, Manta, X.morph, Doc Scott, Akrom, Pish Posh, Stonx, MV, Direct Shift, Unknown Konflikt, Contam, Protoss, Bytecode, Acidion, MYGR, Jane Doe DNB, SeanTron, ESKR, Nox, Insom, Confusion, Subconscious BSC, Needlenose, Hijk, Tschul, Korax, CRS, ARI-ON, Metric, Figure, Quannum Logic, Sindicate, Crackindomes, RCA Trash, J. Augustus, Jay, Lennart Hoffmann, Johannes Soppa, Octane Amy, Ollie Duracell, Dan, Murmuration Events, Lee UHF, BassDrive.com, Sinuous Recordings and moreSubscribe to the podcast: bestdnb.com/podcast  

In this episode, hosts David Millili and Steve Carran sit down with Anthony Vita, VP of Global Partnerships at Revenue Analytics, to explore how modern revenue management is becoming more accessible to independent hotels and boutique operators.Anthony shares his unconventional journey from e-commerce and luxury interiors into hospitality tech, and how that experience helped shape his perspective on data, pricing, and automation. The conversation dives into the launch and expansion of Climber in North America, and how it's aiming to level the playing field between small independent properties and large hotel groups through affordable, intelligent revenue management tools.In this episode, you'll learn: Why Climber is expanding into North America to support independent hotel operators  How Revenue Analytics is working to democratize revenue management tools that were once only available to large hotel chains  Why many independent hotels still rely on spreadsheets and “gut instinct” for pricing—and what's changing  The importance of partnerships across PMS, CRS, and hospitality tech ecosystems in scaling revenue solutions globally  How accessibility and affordability are shaping the future of revenue management for small and mid-sized properties Watch the FULL EPISODE on YouTube: https://youtu.be/3vbrnUkyHaALinks:Anthony on LinkedIn: https://www.linkedin.com/in/vitaanthony/Revenue Analytics: https://www.revenueanalytics.com/For full show notes head to: https://themodernhotelier.com/episode/291Follow on LinkedIn: https://www.linkedin.com/company/the-..Join the conversation on today's episode on The Modern Hotelier LinkedIn pageConnect with Steve and David:Steve: https://www.linkedin.com/in/%F0%9F%8E...David: https://www.linkedin.com/in/david-mil.

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry continue their series on major Express Entry reforms expected in Canada. They explain why a high CRS score may no longer guarantee a realistic path to permanent residence, and break down the growing divide between general draws and category-based draws in Express Entry. Key Topics Discussed The 169 versus 505 CRS paradox General draws versus category-based draws STEM draw blackout and category-based uncertainty High-wage occupations and future CRS changes Key Takeaways A higher CRS score does not always mean a better chance of receiving an ITA. Category-based draws can completely change the outcome for applicants with lower CRS scores. Some categories, including STEM, may remain inactive for long periods despite appearing on IRCC's list. Applicants need to understand where they stand now and prepare before CRS changes arrive. Quotes from the Episode: Mark Holthe: “If your whole plan is, ‘I will just wait for the general cutoff to drift down to my score,' the data is basically telling you that that's not a plan.” Alicia Backman-Beharry: “It is just so important now to be extremely targeted in terms of how you are planning for your future instead of passive.” Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

tracklist and more info: https://www.bestdrumandbass.com/podcast598/Welcome back my friends! we celebrate the new release from Direct Shift & Sez'Nah on Abducted LTD (that is currently in the top 40 DNB releases!) with a guest mix by Sez'Nah, alongside your usual resident madness with Bad Syntax. Lets get the weekend started!Direct Shift ft Sez'Nah - D.Y.C.A.G.Y.S / Bankruptcy [Abducted LTD]Download / Stream: bestdrumandbass.com/altd141/Supported by: MNDSCP, Manta, X.morph, Doc Scott, Akrom, Pish Posh, Stonx, MV, Direct Shift, Unknown Konflikt, Contam, Protoss, Bytecode, Acidion, MYGR, Jane Doe DNB, SeanTron, ESKR, Nox, Insom, Confusion, Subconscious BSC, Needlenose, Hijk, Tschul, Korax, CRS, ARI-ON, Metric, Figure, Quannum Logic, Sindicate, Crackindomes, RCA Trash, J. Augustus, Jay, Lennart Hoffmann, Johannes Soppa, Octane Amy, Ollie Duracell, Dan, Murmuration Events, Lee UHF, BassDrive.com, Sinuous Recordings and moreSubscribe to the podcast: bestdnb.com/podcast

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry continue their series on major Express Entry reforms expected in Canada. They explain why the public consultation on minimum eligibility may not be the reform that most affects applicants, and break down the three tracks applicants need to watch: regulatory reform, CRS changes through ministerial instructions, and category-based draws. Key Topics Discussed Three-track timeline for Express Entry reforms CRS changes versus regulatory amendments Category-based draws and public consultation High-wage occupations and future job offer points Key Takeaways The eligibility merger is important, but it is not the most urgent reform for most applicants. CRS changes could arrive quickly through ministerial instructions and may significantly affect scores. Category-based draws are running on a separate clock and may become even more important as bonus points are removed. Applicants should prepare strategically by keeping as many pathways open as possible. Quotes from the Episode: Mark Holthe: “No longer can you just submit a profile, sit back, and wait for your turn.” Alicia Backman-Beharry: “It's really a matter of being really thoughtful about what you're doing, why you're doing it, and where you want it to take you.” Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

In this month's Cayman Islands Regulatory 15/15 episode, Chris Capewell, Laura Goucke and Yunie Wong review industry consultations, new CRS 2.0 self-certifications and CIMA's 2026 annual AML return season.Still have questions about Common Reporting Standard 2.0, tokenised fund regulation or AML/CFT updates? Join our Lexology webinar on Thursday, 25 June for practical, expert-led insights from Chris Capewell, Patrick Head, Jo Ottaway and Lisa Page: https://lbresearch.zoom.us/webinar/register/7317782516165/WN_Z8FKXKFkQm2AlwoHQfSBgwTo read the 2026 Cayman Islands Regulatory Calendar, visit: https://maples.com/regulatory-round-up/2026-cayman-islands-regulatory-calendar.To read the 2026 BVI Regulatory Calendar, visit: https://isu.pub/MgRPtyFSPEAKERS:Chris Capewell, Partner | +1 345 814 5666 | chris.capewell@maples.com | View bioLaura Goucke, Associate | +1 345 938 5304 | laura.goucke@maples.com | View bioYunie Wong, Legal Manager | +852 9016 0076 | yunie.wong@maples.com | View bioThe contents of this podcast do not constitute legal advice and need to be taken as a general update only.Visit our Regulatory Round-Up Blog for the latest developments and insights in the regulatory landscape.RELATED SERVICES:Maples Group Regulatory and Financial Services AdvisoryWith a depth of experience across all regulated sectors, the Maples Group Regulatory and Financial Services team is positioned to address client needs and sensitivities. We have the largest dedicated Cayman Islands Regulatory and Financial Services team in the offshore market.Follow Us:LinkedIn: https://www.linkedin.com/company/maplesgroup/Instagram: https://www.instagram.com/maplesgroup/Twitter: https://twitter.com/maplesgroupFacebook: https://www.facebook.com/maplesgroup/Website: https://maples.com/podcasts/15-15Blog: https://maples.com/regulatory-round-up

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry continue their series on major Express Entry reforms expected in Canada. They break down the two-track timeline for Express Entry changes, what is expected to change quickly through ministerial instructions, what will take longer through regulatory amendments, and how applicants should assess their current strategy before the deeper reform episodes begin. Key Topics Discussed Two-track timeline for Express Entry reforms Ministerial instructions versus regulatory amendments What is staying stable in Express Entry for 2026 High-wage occupation factors and future CRS changes Key Takeaways Express Entry is evolving, not collapsing, and many core features remain stable for now. Ministerial instruction changes could happen quickly and may affect CRS scoring factors. Regulatory reforms, including a potential merger of FSW, CEC, and FST, are expected later. Applicants should assess whether their occupation, Canadian experience, education, spouse, French, PNP, or job offer strategy may be affected. Quotes from the Episode: Mark Holthe: “Change is here. It is right on the doorstep.” Alicia Backman-Beharry: “It's so helpful to understand which reforms are coming and when they're coming.” Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

Show #1154 The Real Thing 01. John Primer & Friends - We All Need Help (3:46) (Tribute To Theresa's Lounge, Blues House Productions, 2026) 02. Billy Thompson - Truth Come To Power (4:45) (This World, MoMojo Records, 2026) 03. Matthew Patrick - Hi Flyer (3:23) (Red River EP, self-release, 2026) 04. Dave Thomas - Big Fast Car (2:47) (Bridge Street Blues, Blonde On Blonde Records, 2026) 05. Sherri Harding - What's The Matter (With My Heart) (3:05) (Storyland, Instant Replay Music, 2026) 06. Cary Morin - It Matters To You Now (6:13) (Songs From Anguilla 2026 EP, Maple Street Music, 2026) 07. Billy Price - Exit Strategy (4:03) (Random Madness, Get Hip Records, 2026) 08. Geiger von Müller - After The Slide (0:55) (Neocubist Blues, self-release, 2026) 09. Nicky T & the Snake Charmers - Ain't Wasting Time (10:15) (Ain't Wasting Time, self-release, 2026) 10. Satori - Tease Blues (3:34) (The Seat Of The Soul, Klopotec Records, 2026) 11. Duke Robillard & his All Star Band - Feel My Cares (4:44) (Blast Off!, Nola Blue Records, 2026) 12. Steve Marriner - Hellbound For Heaven (3:49) (Hear My Heart, Cordova Bay Records, 2025) 13. The Shaelyn Band - I Won't Sell My Soul (4:12) (Chapter 3, House Of Berry Records, 2026) 14. Chris Bergson - Little Girl Blue (6:21) (East River Blues, CRS/2 Shirts Records, 2026) 15. Carmen Ratti Band (ft. Jill Dineen) - I Can See (3:52) (Come To Me, MoMojo Records, 2026) 16. Jump 66 - Straight From The Bottle (5:00) (Every Dog Has Its Day, self-release, 2026) 17. Royal & Toulouse - I See One Thing (5:53) (Tell The Devil, Little Town Sound, 2025) 18. Jason Ricci & the Bad Kind - Sick Of This Shit (8:30) (13 Hours, Gulf Coast Records, 2026) 19. ElectroBluesSociety - Be Alright (5:04) (Bluestronica Midnight Sessions, Black & Tan Records, 2026) Bandana Blues is and will always be a labor of love. Please help Spinner deal with the costs of hosting & bandwidth. Visit www.bandanablues.com and hit the tipjar. Any amount is much appreciated, no matter how small. Thank you.

Tracklist: https://www.bestdrumandbass.com/podcast597/This week is extra special: Tom Finster has a new self released album dropping, and as you will soon see, it is full of amazingly lush and wonderful tunes. We are also celebrating the latest release on Abducted LTD in the resident seat, so lock it in, and lets rock it out!Direct Shift ft Sez'Nah - D.Y.C.A.G.Y.S / Bankruptcy [Abducted LTD]Download / Stream: bestdrumandbass.com/altd141/Supported by: MNDSCP, Manta, X.morph, Doc Scott, Akrom, Pish Posh, Stonx, MV, Direct Shift, Unknown Konflikt, Contam, Protoss, Bytecode, Acidion, MYGR, Jane Doe DNB, SeanTron, ESKR, Nox, Insom, Confusion, Subconscious BSC, Needlenose, Hijk, Tschul, Korax, CRS, ARI-ON, Metric, Figure, Quannum Logic, Sindicate, Crackindomes, RCA Trash, J. Augustus, Jay, Lennart Hoffmann, Johannes Soppa, Octane Amy, Ollie Duracell, Dan, Murmuration Events, Lee UHF, BassDrive.com, Sinuous Recordings and moreSubscribe to the podcast: bestdnb.com/podcast

Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results.  Read more about this abstract on the AAN website.   Show transcript:  Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.  

Dr. Shuvro Roy and Dr. Amanda Piquet discuss a brief overview of stiff person syndrome, as well as the trial and the trial results.  Read more about this abstract on the AAN website.   Show transcript:  Dr. Shuvro Roy: Hi, this is Shuvro Roy from the University of Washington and welcome to today's Neurology Minute. I just wrapped a longer conversation with Amanda Piquet from the University of Colorado Anschutz School of Medicine. We were just talking about the recent Phase 2 trial evaluating Miv-cel Kyverna Therapeutics' anti-CD19 CAR T-cell therapy in patients with Stiff Person Syndrome. Amanda, would you mind taking us through a brief overview of SPS as well as the trial and their trial results? Dr. Amanda Piquet: So Stiff Person Syndrome, or SPS, is a rare disabling autoimmune neurologic disease with a major unmet need. About 80% of patients ultimately lose their mobility and we currently have no FDA approved therapies. Existing treatments like IVIG, rituximab, and plasmapheresis are all used off label, often requiring chronic dosing and frequently failing to stop progression. KYSA-8 is a registrational Phase 2 study of 26 patients with refractory SPS. Patients experienced rapid, statistically significant and clinically meaningful improvement across all primary and secondary endpoints. Primary endpoint was the timed 25-foot walk. And this improved by a median of 46% at 16 weeks. Of patients requiring walking aids at baseline, about two thirds no longer needed them by week 16 to complete that 25-foot walk. Some patients who had struggled to walk were even able to run again after treatment. Another key finding was that all patients discontinued chronic immune therapies and remained off treatment as of the last follow-up. From a safety standpoint, miv-cel was generally well tolerated, with no high grade CRS or ICANS observed. In my opinion, these outcomes are unlike anything we've seen previously with Stiff Person Syndrome and may represent a paradigm shift, not only for SPS, but potentially for other antibody-mediated neurologic diseases more broadly. Dr. Shuvro Roy: Just curious, are there any upcoming implications for the application of this treatment for patients, you think, in the coming year or so? Dr. Amanda Piquet: Kyverna, the company who developed miv-cel, has initiated a rolling BLA with the FDA for potential approval and this would be, if approved, the first CAR-T therapy for SPS. So we're anxiously awaiting the outcome of that process. Dr. Shuvro Roy: Fantastic. Amanda, thank you so much for your time. And if you are intrigued and want to know more details behind the findings in the study as well as a conversation around CAR-T therapy for autoimmune neurologic disease as a whole, I encourage you to check out the Neurology Podcast feed for our full conversation there. Thanks for tuning in.  

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry continue their series on major Express Entry reforms expected in Canada. They examine IRCC's own data on Express Entry outcomes, why Canada is still proposing major reforms to a system that appears to be working, and how high wages, job offers, Canadian experience, French language ability, category-based draws, and immigration levels could reshape future permanent residence strategies. Key Topics Discussed IRCC data on Express Entry outcomes High-wage Canadian work experience and job offers Immigration levels and temporary resident reductions Why Express Entry reforms are being proposed Key Takeaways Express Entry applicants generally have strong employment, wage, and occupation-match outcomes. IRCC appears to be recalibrating the system toward high-wage earners and stronger economic predictors. Reduced temporary resident and permanent resident targets are making PR planning more competitive. Applicants should reassess CRS strategies that rely on bonus points, occupation categories, French, Canadian education, and timing. Quotes from the Episode: Mark Holthe: “Does my current CRS strategy, the factors I'm counting on, the timing I've planned, the profile I've built still make sense under a system being recalibrated toward high-wage earnings?” Alicia Backman-Beharry: “They are changing things not because they don't work, not because they're broken, but because they want to make it better.” Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

Episode Summary: In this episode, Mark Holthe and Alicia Backman-Beharry launch a new series on major Express Entry reforms expected in Canada. They explain how Express Entry works, why it is not a permanent residence program itself, what applicants need to understand about the current system, and how upcoming changes to CRS points, category-based draws, and program structures could affect future permanent residence strategies. Key Topics Discussed Express Entry basics Federal Skilled Worker, Canadian Experience Class, and Federal Skilled Trades CRS score factors Upcoming Express Entry reforms Key Takeaways Express Entry is a system for managing economic immigration applications, not a program itself. Being in the Express Entry pool does not guarantee an invitation to apply. Canadian Experience Class and category-based draws are currently playing a major role. Upcoming reforms could significantly change how CRS points are awarded. Quotes from the Episode: Mark Holthe: “There's nothing more important than knowing what's coming and then doing what you can to increase your chances of success.” Alicia Backman-Beharry: “What people do right now is going to impact whether their profile is one that has a chance in the future.” Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

Tracklist and more info: https://www.bestdrumandbass.com/podcast596/Happy Friday my friends! We have a VERY SPECIAL edition this week, as one of the long time Abducted artists BINARY are here for a guest mix to celebrate their epic release on Skamele! Lock it in, and be ready to rock out my friends. The weekend has begun! The In Kill - Go Forth / Sick [Abducted LTD]Download / Stream: bestdrumandbass.com/altd140/Supported by: Doc Scott, Stonx, Akrom, Bad Syntax, 5AH5H, Direct Shift, Bytecode, Protoss, Acidion, Contam, Neothrope, Oalky, ESKR, Figure, DJ Odi, ARI-ON, Hijk, Metric, Quannum Logic, Malasuerte, Nox, Subcat, Korax, CRS, SeanTron, Autopsy, RCA Trash, J. Augustus, Sinuous Recordings, Tschul, Reverend Kathy Russell, John Morgan, Inside Dnb, Chris, Jay, Johannes Soppa, Lennart Hoffmann, Subconscious BSC, Critical Control Point, Crackindomes, Octane Amy, Confusion and more!Subscribe to the podcast: bestdnb.com/podcast

In the 6th chapter of Matthew's gospel, Jesus teaches his disciples how to pray, introducing what today we call the "Our Father," or the "Lord's Prayer." But Jesus imparts this prayer in the context of various instructions on the many ways we shouldn't pray. Don't pray in public for everyone to see. Don't put on a gloomy face. Then, in the following chapter, he says: "Not everyone who says to me, 'Lord, Lord,' will enter the kingdom of heaven, but only the one who does the will of my Father in heaven." So Christians should pray. But Christians should also, it seems, be wary about praying the wrong way. This opens up intriguing questions about what it means to pray, whether there are things we should or shouldn't pray for, and what it means for a prayer to be answered.  On this episode of Glad You Asked, the hosts talk with award-winning writer Laura Kelly Fanucci about the point of prayer.  Fanucci is the author of a number of books, most recently Living Easter: 50 Days to Practice Resurrection Joy (Liturgical Press, 2026). She has written for U.S. Catholic as well as OSV News Service, America Magazine, and on two popular substacks. Her work has also been featured on the Hallow and Ritual apps, and in popular outlets including NPR's Morning Edition, On Being, and The Kelly Clarkson Show.  You can learn more about this topic, and read some of Fanucci's work, in these links. Living Easter: 50 Days to Practice Resurrection, by Laura Kelly Fanucci The Holy Labor: Original essays on theology & spirituality from Laura Kelly Fanucci "Should you request prayers on social media?" by Teresa Coda "Can prayer heal?" by Teresa Coda "Prayer must lead to practical solutions," by Shireen Korkzan "Pope Leo says God rejects prayers of leaders who wage wars," by Joshua McElwee This episode is sponsored by Catholic Relief Services. Prayer connects us to God and to one another, and CRS puts that connection into action by serving people facing hunger, violence and displacement worldwide. Through shared prayers and humanitarian response, CRS invites you to live out your faith through service to others. Learn more about CRS' work at crs.org.

Full episode info here: https://www.bestdrumandbass.com/podcast595/#NEUROWEIRDO is here yet again, and we are back and a pocket full of streaming troubles couldnt stop us! In the guest mix this week we have the ATL homie DEMOTANK slaying, and in the resident mix we are pushing the massive new single by THE IN KILL! Lock it in, its time to rock it out! The In Kill - Go Forth / Sick [Abducted LTD]Download / Stream: bestdrumandbass.com/altd140/Supported by: Doc Scott, Stonx, Akrom, Bad Syntax, 5AH5H, Direct Shift, Bytecode, Protoss, Acidion, Contam, Neothrope, Oalky, ESKR, Figure, DJ Odi, ARI-ON, Hijk, Metric, Quannum Logic, Malasuerte, Nox, Subcat, Korax, CRS, SeanTron, Autopsy, RCA Trash, J. Augustus, Sinuous Recordings, Tschul, Reverend Kathy Russell, John Morgan, Inside Dnb, Chris, Jay, Johannes Soppa, Lennart Hoffmann, Subconscious BSC, Critical Control Point, Crackindomes, Octane Amy, Confusion and more!Subscribe to the podcast: bestdnb.com/podcast

Beau Welling joins CRS to talk about whether the current golf course renovation boom is warranted or driven by FOMO,  and how land planning fits into his design business. He also discusses designing the green and virtual holes for TGL, what golf can learn from curling, and gives updates on major projects at Kiawah and Lake Oconee.

Tracklist and more info: https://www.bestdrumandbass.com/podcast593/Welcome back my friends, we have another wicked week in store for you! HIJK is here to present a wicked mix in the guest spot, and as always we have BAd Syntax kicking things off. So lock it in, and lets rock it out! Subscribe to the podcast: bestdnb.com/podcast  KORAX - Scorched Planet / Dropship [Abducted LTD]Download / Stream: bestdrumandbass.com/altd139/Supported by: Doc Scott, Pish Posh, Akrom, Stonx, 5HA5H, Bad Ace, Quannum Logic, Sinuous Recordings, MYGR, Korax, ESKR, Manta, Contam, Nox, Diode, Acidion, Unknown Konflikt, Malasuerte, CRS, X.morph, Sindicate, GroVe, Subcat, Protoss, Bytecode, Plasmator, ARI-ON, Crackindomes, Affirmation, Tschul, Autopsy, Ollie Duracell, RCA Trash, Confusion, Critical Control Point, Octane Amy, BassDrive.com, Lee UHF, Inside Dnb, Lennart Hoffmann, Johannes Soppa, Knoxz, MV, Metric, J. Augustus and more! 

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of bispecific antibodies approved for multiple myeloma. Joined by myeloma specialists Dr. Hamza Hashmi from Memorial Sloan Kettering and Dr. Cesar Rodriguez from Mount Sinai, they discussed the latest updates, clinical pearls, and practical insights for community oncologists. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics included: Overview of bispecific antibodies, focusing on GPRC5D and BCMA-targeted therapies. Detailed discussion on talquetamab, teclistamab, elranatamab, and linvoseltamab, including dosing, side effects, and management strategies. Insights on managing cytokine release syndrome (CRS), neurotoxicity, and other side effects like dysgeusia, skin toxicity, and infections. Prophylactic measures, including the use of IVIG and tocilizumab, to enhance patient care and quality of life. Whether you're a healthcare professional or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology! #MultipleMyeloma, #BispecificAntibody, #ICANS, #CRSmanagement, #OncologyBrothers

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net.Today on the emDOCs cast with Brit Long, MD (@long_brit), we cover stercoral colitis. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play Send us Fan Mail

Show #1149 Late But Long 01. Krissy Matthews & the Vikings - Teasin' Times (4:00) (Rock And Roll Soldier, Ruf Records, 2026) 02. Gary Dranow - No More Wars (Part 2) (4:07) (Plays The Blues, self-release, 2026) 03. Misty Blues (ft. Lady Bianca) - Trifling Man (4:07) (Still Ticking, Guitar One Records, 2026) 04. Scott O'Neal Band - Time For Walkin' (4:56) (Call Me Mr. Blues, Lightning In A Bottle Records, 2026) 05. TuskHead - Out Of My Mind (4:12) (One Step Forward & Two Steps Back EP, Migrant Records, 2026) 06. Bob Corritore & Carla Denise - Wild As You Can Be (3:42) (Ernestine Blues, SWMAF/VizzTone Records, 2026) 07. Carmen Ratti Band (ft. Jill Dineen) - Pretty Good Man (4:06) (Come To Me, MoMojo Records, 2026) 08. GA-20 with Charlie Musselwhite - Crazy Love (3:15) (Blues Now, New West Records, 2026) 09. Greg Piccolo & Heavy Juice - Break In The Clouds (4:26) (Who Knows What The Future Holds, MoMojo Records, 2026) 10. F.A.R. Trio - When You Put That Dress On (5:09) (Single, self-release, 2026) 11. Drum & Beeker - Heksepoeier (4:15) (Kapot Ver Weg, Woo-Hoo Records, 2026) 12. Ghalia Volt - Let Yo' Hair Down (3:30) (Burn The House Down, Ruf Records, 2026) 13. Doctor Tongue - Pickle (4:38) (Fly, Jetpack Records, 2026) 14. Earl Nelson & the Company - John Henry (3:34) (Single, self-release, 2026) 15. The Name Droppers - Let's Live Together (3:56) (Let's Live Together, Horizon Music Group, 2026) 16. Chris O'Leary - Bad Decisions (4:21) (Blue Collar, Alligator Records, 2026) 17. Shaun Murphy - I'm Gonna Take The Money (3:21) (Brand New Blues, Vision Wall Records, 2026) 18. The CD Woodbury Trio - A Song In There (3:50) (Bulldog, Lightning In A Bottle Records, 2026) 19. Joey Quiñones - Driftin' (4:01) (Inna Soul Steady Situation, Colemine Records, 2026) 20. Samantha Martin & Delta Sugar - Don't Have To Be (3:02) (A Beautiful Buzz, Gypsy Soul Records, 2026) 21. Troy Mercy - Cheap Machine (3:58) (Let the Night Begin, Gitcha Records, 2026) 22. Stefan Hillesheim Band - Sick Of Your Love (3:57) (Live At Chicago Blues Fest, Stella Blue Music, 2026) 23. The Bird Experience - She's So Fine (3:45) (The Bird Experience, Suburban Records, 2026) 24. The Davidson Trio - Follow You (5:13) (Follow You EP, self-release, 2026) 25. Gina Coleman - Fore Day Creep (3:25) (Uncrowned: A Tribute To Ida Cox, Guitar One Records, 2026) 26. Chris Bergson - Driftin' (4:45) (East River Blues, CRS/2 Shirts Records, 2026) Bandana Blues is and will always be a labor of love. Please help Spinner deal with the costs of hosting & bandwidth. Visit www.bandanablues.com and hit the tipjar. Any amount is much appreciated, no matter how small. Thank you.

Tracklist and more info: https://www.bestdrumandbass.com/podcast592/We are back for another BANGER of a session this week my friends! We have MOFW with his debut on the podcast bringing the heavier side of DNB, and you have the usual resident mix with Bad syntax to get things shaking. Lock it in, and lets rock it out. The weekend has begun! Subscribe to the podcast: bestdnb.com/podcast  KORAX - Scorched Planet / Dropship [Abducted LTD]Download / Stream: bestdrumandbass.com/altd139/Supported by: Doc Scott, Pish Posh, Akrom, Stonx, 5HA5H, Bad Ace, Quannum Logic, Sinuous Recordings, MYGR, Korax, ESKR, Manta, Contam, Nox, Diode, Acidion, Unknown Konflikt, Malasuerte, CRS, X.morph, Sindicate, GroVe, Subcat, Protoss, Bytecode, Plasmator, ARI-ON, Crackindomes, Affirmation, Tschul, Autopsy, Ollie Duracell, RCA Trash, Confusion, Critical Control Point, Octane Amy, BassDrive.com, Lee UHF, Inside Dnb, Lennart Hoffmann, Johannes Soppa, Knoxz, MV, Metric, J. Augustus and more! 

Tracklist and more info: https://www.bestdrumandbass.com/podcast591/New release day has arrived my friends. Today we celebrate the EPIC new drop by our very own North American legend KORAX! On top of that, the rising stars from the UK, Titanz (UK) step into the guest mix to celebrate their very own new and HEAVY single. Lock it in, it is a big week! Subscribe to the podcast: bestdnb.com/podcast  KORAX - Scorched Planet / Dropship [Abducted LTD]Download / Stream: bestdrumandbass.com/altd139/Supported by: Doc Scott, Pish Posh, Akrom, Stonx, 5HA5H, Bad Ace, Quannum Logic, Sinuous Recordings, MYGR, Korax, ESKR, Manta, Contam, Nox, Diode, Acidion, Unknown Konflikt, Malasuerte, CRS, X.morph, Sindicate, GroVe, Subcat, Protoss, Bytecode, Plasmator, ARI-ON, Crackindomes, Affirmation, Tschul, Autopsy, Ollie Duracell, RCA Trash, Confusion, Critical Control Point, Octane Amy, BassDrive.com, Lee UHF, Inside Dnb, Lennart Hoffmann, Johannes Soppa, Knoxz, MV, Metric, J. Augustus and more!